High throughput screening identified a phenoxyacetic acid scaffold as a novel CRTh2 receptor antagonist chemotype, which could be optimised to furnish a compound with functional potency for inhibition of human eosinophil shape change and oral bioavailability in the rat. (c) 2007 Elsevier Ltd. All rights reserved.
High throughput screening identified a phenoxyacetic acid scaffold as a novel CRTh2 receptor antagonist chemotype, which could be optimised to furnish a compound with functional potency for inhibition of human eosinophil shape change and oral bioavailability in the rat. (c) 2007 Elsevier Ltd. All rights reserved.
作者:David A. Sandham、Clive Aldcroft、Urs Baettig、Lucy Barker、David Beer、Gurdip Bhalay、Zarin Brown、Gerald Dubois、David Budd、Louise Bidlake、Emma Campbell、Brian Cox、Brian Everatt、David Harrison、Catherine J. Leblanc、Jodie Manini、Rachael Profit、Rowan Stringer、Katy S. Thompson、Katharine L. Turner、Morris F. Tweed、Christoph Walker、Simon J. Watson、Steven Whitebread、Jennifer Willis、Gareth Williams、Caroline Wilson
DOI:10.1016/j.bmcl.2007.05.019
日期:2007.8
High throughput screening identified a phenoxyacetic acid scaffold as a novel CRTh2 receptor antagonist chemotype, which could be optimised to furnish a compound with functional potency for inhibition of human eosinophil shape change and oral bioavailability in the rat. (c) 2007 Elsevier Ltd. All rights reserved.